Conference Proceedings
Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study.
Danny Rischin, Madeleine T King, Lizbeth M Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E Jackson, Mathias Bressel, Alan Herschtal, Fisher Richard, Tsien Fua, Charles Lin, Chen-Shin Liu, Brett Gordon Maxwell Hughes, Margie McGrath, Lachlan McDowell, June Corry
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
Abstract
6012 Background: The excellent prognosis of patients with low risk HPV associated oropharyngeal squamous cell carcinoma has led to concerns about overtreatment and excessive toxicity with radiotherapy and cisplatin, leading to interest in de-intensification trials. We investigated whether cetuximab, an EGFR targeting antibody, when combined with radiotherapy would result in a decrease in symptom burden and toxicity with similar efficacy when compared to weekly cisplatin. Methods: TROG 12.01, a randomised, multicentre trial involving 15 sites in Australia and New Zealand enrolled patients with HPV associated oropharyngeal squamous cell carcinoma, AJCC 7th edition Stage III (excluding T1-2N1)..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
[ "National Health and Medical Research Council (Project Grant 1047673)", "Pharmaceutical/Biotech Company" ]